Hidrasec Bongs Lecture

8,154 views

Published on

10th Post Graduate Course PAFP Pangasinan Chapter

Published in: Health & Medicine, Business
1 Comment
9 Likes
Statistics
Notes
  • good krub
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
No Downloads
Views
Total views
8,154
On SlideShare
0
From Embeds
0
Number of Embeds
114
Actions
Shares
0
Downloads
0
Comments
1
Likes
9
Embeds 0
No embeds

No notes for slide
  • This slide set is prepared for the Scientific and Interactive Meetings (SIM) to be conducted for Racecadotril (Hidrasec). The title of this module is “A Novel Approach in the Treatment of Acute Diarrhea”.
  • Hidrasec Bongs Lecture

    1. 1. A Novel Approach in the Treatment of Acute Diarrhea ARBEL MONDONEDO,MD,FPCP, FPSG,FPSDE
    2. 2. <ul><li>Fluid and electrolyte balance and diarrhea </li></ul><ul><li>Burden of diarrhea and its management </li></ul><ul><li>Racecadotril – an intestinal antisecretory agent </li></ul><ul><li>Clinical trials </li></ul><ul><li>Safety and tolerability profile </li></ul><ul><li>Conclusions </li></ul>PRESENTATION OUTLINE INTRODUCTION
    3. 3. FLUID AND ELECTROLYTE BALANCE IN THE INTESTINES
    4. 4. DAILY WATER EXCHANGES Sellin JH. Intestinal electrolyte absorption and secretion. In: Feldman M, et al, eds. Sleisenger & Fordtrans Gastrointestinal and Liver Disease . 6 th ed. 1998: 1451-1471 FLUID AND ELECTROLYTE BALANCE IN THE INTESTINES Food Fluid intake Water absorption Water secretion (<5ml/kg – children) (< 200 ml – adults) Exogenous sources: (2 liters) Endogenous sources: (7 liters) Saliva Gastric juices Intestinal secretions Pancreatic juices Biliary secretions
    5. 5. Duodenum / Jejunum 5.5 liters Endogenous secretions: intestinal, pancreatic, salivary, biliary and gastric juices 7 liters Sellin JH. Intestinal electrolyte absorption and secretion. In: Feldman M, et al, eds. Sleisenger & Fordtrans. Gastrointestinal and Liver Disease . 6 th ed. 1998: 1451-1471 Ileum 2 liters Colon/ Rectum 1.3 liters Stool (<5ml/kg – children) (< 200 ml – adults) Food and fluid intake (drinks, meals…) 2 liters FLUID AND ELECTROLYTE BALANCE IN THE INTESTINES DAILY WATER EXCHANGES
    6. 6. Glucose, Na + , K + , Cl - , Water WATER FOLLOWS THE MOVEMENT OF ELECTROLYTES AND GLUCOSE Gut lumen Enterocyte FLUID AND ELECTROLYTE BALANCE IN THE INTESTINES
    7. 7. Crypt: Secretion Villus Tip: Absorption Farthing M. Digestive Diseases (Review Article) 2006;24:47-58 NORMAL STATE FLUID AND ELECTROLYTE BALANCE IN THE INTESTINES
    8. 8. REGULATION OF INTESTINAL SECRETION Enkephalin - opioid neurotransmitter that binds to delta receptors to reduce the levels of cAMP Schwartz. International Journal of Antimicrobial Agents 14(2000) 75-79 VIP (Vasoactive Intestinal Peptide) Prostaglandin E 2 - increase cAMP levels Cyclic AMP - induces secretion of water and electrolytes Enkephalinase - enzyme that degrades enkephalins FLUID AND ELECTROLYTE BALANCE IN THE INTESTINES
    9. 9. OPIOIDS AND THEIR RECEPTORS Exogenous - Morphine - Loperamide µ (mu) has inhibitory effects on intestinal smooth muscles  (delta) decreases cAMP formation +++ +++ + + Endogenous - Enkephalins + +++ Farthing M. Digestive Diseases (Review Article) 2006;24:47-58 Opioids Opioid receptors FLUID AND ELECTROLYTE BALANCE IN THE INTESTINES
    10. 10. c-AMP ATP VIP Prostaglandins Schwartz. International Journal of Antimicrobial Agents 14(2000) 75-79 Enkephalins REGULATION OF WATER AND ELECTROLTYE SECRETION – NORMAL STATE Enkephalinase Delta receptor FLUID AND ELECTROLYTE BALANCE IN THE INTESTINES
    11. 11. DIARRHEA
    12. 12. <ul><li>Passage of abnormally liquid or unformed stools at an increased frequency </li></ul><ul><li>Stool weight > 200 grams / day </li></ul>DIARRHEA 1,2 1. Harrison’s Principles of Internal Medicine 17 th Edition. Volume 1 2. The Treatment of Diarrhea: A manual for physicians and other senior health workers, Department of Child and Adolescent Health and Development, World Health Organization 2005 Consistency of the stools is more important than the number of stools. Frequent passing of formed stools is NOT diarrhea. DIARRHEA
    13. 13. Over-secretion of water leads to diarrhea. Hypersecretion DIARRHEA (> 200 grams /day) Secretion Absorption Absorption Normal State DIARRHEA DIARRHEA
    14. 14. <ul><li>Acute diarrhea </li></ul><ul><li>- < 2 weeks duration </li></ul><ul><li>- more than 90% are caused by infectious agents </li></ul><ul><li>- often accompanied by vomiting, fever, and abdominal pain </li></ul><ul><li>Persistent diarrhea </li></ul><ul><li>2 to 4 weeks duration </li></ul><ul><li>Chronic diarrhea </li></ul><ul><li>> 4 weeks duration </li></ul><ul><li>needs further evaluation to exclude serious underlying pathology </li></ul><ul><li>usually non-infectious in origin </li></ul>ACUTE, PERSISTENT, AND CHRONIC DIARRHEA DIARRHEA Harrison’s Principles of Internal Medicine 17 th Edition. Volume 1
    15. 15. <ul><li>Bacteria: - ETEC - V. cholerae, V. parahaemolyticus - Aeromonas, Plesiomonas, Shigella, Salmonella , EHEC </li></ul><ul><li>Viruses: - Rotavirus - Enteric adenovirus (types 40 & 41) - SRSVs </li></ul><ul><li>Protozoa: - C. parvum, G. intestinalis </li></ul><ul><li>Duration: < 14 days; lasts several hours or days </li></ul>ACUTE WATERY DIARRHEA (Infectious) 1,2 1. Farthing M. Digestive Diseases (Review Article) 2006;24:47-58 2. The Treatment of Diarrhea: A manual for physicians and other senior health workers, Department of Child and Adolescent Health and Development, World Health Organization 2005 DIARRHEA
    16. 16. NORMAL VILLI BLUNTED VILLI ACUTE WATERY DIARRHEA (Infectious) DIARRHEA
    17. 17. Destruction of enterocytes: EIEC, rotavirus, shigella Defective absorption Hypersecretion: Vibrio cholerae , rotavirus, ETEC, shigella IMBALANCE BETWEEN ABSORPTION AND SECRETION The Treatment of Diarrhea: A manual for physicians and other senior health workers, Department of Child and Adolescent Health and Development, World Health Organization 2005 ACUTE WATERY DIARRHEA (Infectious) DIARRHEA
    18. 18. BURDEN OF DIARRHEA
    19. 19. More than 1 billion people suffer one or more episodes of acute diarrhea each year. Because of poor sanitation and more limited access to health care, acute infectious diarrhea remains one of the most common causes of mortality in developing countries, particularly among children. BURDEN OF DIARRHEA DIARRHEA IN DEVELOPING COUNTRIES Harrison’s Principles of Internal Medicine 17 th Edition. Volume 1
    20. 20. DIARRHEA IN THE PHILIPPINES *rate/100,000 of sex-specific population 2003 Annual Report Field Health Service Information System, 2000 Philippine Health Statistics, Department of Health, Philippines 2nd leading cause of morbidity (general population) BURDEN OF DIARRHEA
    21. 21. MANAGEMENT OF DIARRHEA
    22. 22. <ul><li>The decision to evaluate acute diarrhea depends on its severity and duration, and on various host factors. </li></ul>APPROACH TO THE PATIENT WITH ACUTE DIARRHEA Indications for evaluation: profuse diarrhea with dehydration grossly bloody stools fever ≥ 38.5 o C duration > 48 hours without improvement new community outbreaks severe abdominal pain in patients > 50 years, and elderly or immunocompromised patients MANAGEMENT OF DIARRHEA Harrison’s Principles of Internal Medicine 17 th Edition. Volume 1
    23. 23. Fluid and electrolyte replacement are of central importance to all forms of acute diarrhea. MANAGEMENT OF DIARRHEA THE TREATMENT OF ACUTE DIARRHEA In moderately severe, non-febrile and non-bloody diarrhea, antimotility antisecretory agents can be useful adjuncts to control symptoms. Judicious use of antibiotics is appropriate in selected instances of acute diarrhea. Harrison’s Principles of Internal Medicine 17 th Edition. Volume 1
    24. 24. UNMET MEDICAL NEEDS IN THE TREATMENT OF ACUTE DIARRHEA
    25. 25. LIMITATIONS OF CURRENT THERAPY Fluid replacement - No significant reduction of diarrhea - Diarrhea may continue “ Antidiarrheals” - Limited efficacy - CNS effects - Bloating - Rebound constipation Antibiotics - Resistance - Unwanted adverse effects Farthing M. Digestive Diseases (Review Article) 2006;24:47-58 UNMET MEDICAL NEEDS IN THE TREATMENT OF ACUTE DIARRHEA
    26. 26. inhibits fluid secretion by intestinal mucosa has a rapid onset of action has limited constipating effects has a high therapeutic index has minimal central nervous system effects has low abuse potential Edelman R. Prevention and treatment of infectious diarrhea. Speculations on the next 10 years. Am J Med 1985;78:99-106. UNMET MEDICAL NEEDS IN THE TREATMENT OF ACUTE DIARRHEA THE IDEAL TREATMENT FOR ACUTE DIARRHEA
    27. 27. Prevention of Dehydration and Control of Diarrhea Fluid replacement alone Fluid replacement with anti-secretory agent UNMET MEDICAL NEEDS IN THE TREATMENT OF ACUTE DIARRHEA THE IDEAL TREATMENT FOR ACUTE DIARRHEA
    28. 28. inhibits fluid secretion by intestinal mucosa has a rapid onset of action has limited constipating effects has a high therapeutic index has minimal central nervous system effects has low abuse potential Racecadotril was developed specifically with these characteristics in mind. 2 1. Edelman R. Prevention and treatment of infectious diarrhea. Speculations on the next 10 years. Am J Med 1985;78:99-106. 2. Lecomte JM. International Journal of Antimicrobial Agents 14 (2000) 81-87 THE IDEAL TREATMENT FOR ACUTE DIARRHEA 1 UNMET MEDICAL NEEDS IN THE TREATMENT OF ACUTE DIARRHEA
    29. 29. RACECADOTRIL: AN INTESTINAL ANTISECRETORY AGENT
    30. 30. REGULATION OF INTESTINAL SECRETION Enkephalin - opioid neurotransmitter that binds to delta receptors to reduce the levels of cAMP Schwartz. International Journal of Antimicrobial Agents 14(2000) 75-79 VIP (Vasoactive Intestinal Peptide) Prostaglandin E 2 - increase cAMP levels Cyclic AMP - induces secretion of water and electrolytes Enkephalinase - enzyme that degrades enkephalins RACECADOTRIL: AN INTESTINAL ANTISECRETORY AGENT
    31. 31. OPIOIDS AND THEIR RECEPTORS Exogenous - Morphine - Loperamide µ (mu) has inhibitory effects on intestinal smooth muscles  (delta) decreases cAMP formation +++ +++ + + Endogenous - Enkephalins + +++ Farthing M. Digestive Diseases (Review Article) 2006;24:47-58 Opioids Opioid receptors RACECADOTRIL: AN INTESTINAL ANTISECRETORY AGENT
    32. 32. c-AMP ATP VIP Prostaglandins Schwartz. International Journal of Antimicrobial Agents 14(2000) 75-79 Enkephalins REGULATION OF WATER AND ELECTROLTYE SECRETION – NORMAL STATE Enkephalinase Delta receptor RACECADOTRIL: AN INTESTINAL ANTISECRETORY AGENT
    33. 33. c-AMP ATP Schwartz. International Journal of Antimicrobial Agents 14(2000) 75-79 Enkephalins Enkephalinase Delta receptor Toxic peptides from viruses / bacteria REGULATION OF INTESTINAL SECRETION - HYPERSECRETORY STATE RACECADOTRIL: AN INTESTINAL ANTISECRETORY AGENT
    34. 34. c-AMP ATP Schwartz. International Journal of Antimicrobial Agents 14(2000) 75-79 Enkephalins Enkephalinase Delta receptor Toxic peptides from viruses / bacteria Racecadotril MODE OF ACTION OF RACECADOTRIL - NORMALIZATION OF SECRETION RACECADOTRIL: AN INTESTINAL ANTISECRETORY AGENT
    35. 35. RACECADOTRIL, a prodrug of THIORPHAN, a potent enkephalinase inhibitor Schwartz. International Journal of Antimicrobial Agents 14(2000) 75-79 RACECADOTRIL: AN INTESTINAL ANTISECRETORY AGENT RACECADOTRIL THIORPHAN (potent-enkephalinase inhibitor) (Non-specific esterase) Hydrolysis
    36. 36. RACECADOTRIL (pro-drug) THIORPHAN (active metabolite) Schwartz. International Journal of Antimicrobial Agents 14(2000) 75-79 RACECADOTRIL: AN INTESTINAL ANTISECRETORY AGENT RACECADOTRIL, a prodrug of THIORPHAN, a potent enkephalinase inhibitor
    37. 37. As the concentration of thiorphan increases, enkephalin levels also increase. Inactivation of endogenous enkephalins by enkephalinase Schwartz. International Journal of Antimicrobial Agents 14(2000) 75-79 RACECADOTRIL: AN INTESTINAL ANTISECRETORY AGENT RACECADOTRIL, a prodrug of THIORPHAN, a potent enkephalinase inhibitor
    38. 38. Enkephalinase inhibition kinetics in healthy volunteers after a single oral dose (100 mg) Lecomte JM. International Journal of Antimicrobial Agents 14 (2000) 81-87 ONSET OF ACTION OF RACECADOTRIL RACECADOTRIL: AN INTESTINAL ANTISECRETORY AGENT
    39. 39. ANTI-SECRETORY ACTIVITY OF RACECADOTRIL Primi et al, Alimentary Pharmacology and Therapeutics 1999; 13(Suppl.6): 3-7. RACECADOTRIL: AN INTESTINAL ANTISECRETORY AGENT Effect of Racecadotril on cholera toxin-induced hypersecretion in dogs
    40. 40. Hinterleitner TA et al. Eur J Gastroenterol Hepatol 1997;9:887-91. Effect of Racecadotril (a single oral dose of 300 mg) on cholera toxin-induced water secretion in healthy adult subjects ANTI-SECRETORY ACTIVITY OF RACECADOTRIL RACECADOTRIL: AN INTESTINAL ANTISECRETORY AGENT
    41. 41. CLINICAL TRIALS
    42. 42. INFANTS AND CHILDREN Eduardo Salazar-Lindo, M.D. et al. The New England Journal of Medicine 2000; 343:463-467 RACECADOTRIL IN THE TREATMENT OF ACUTE WATERY DIARRHEA IN CHILDREN
    43. 43. <ul><li>STUDY DESIGN </li></ul><ul><ul><li>– Randomized, double-blind, placebo-controlled study with 2 parallel groups </li></ul></ul><ul><li>OBJECTIVE </li></ul><ul><ul><li>– To assess the efficacy and safety of racecadotril as an adjunct to oral rehydration therapy for children with acute watery diarrhea </li></ul></ul>RACECADOTRIL IN THE TREATMENT OF ACUTE WATERY DIARRHEA IN CHILDREN (Salazar-Lindo et al.) <ul><li>TREATMENT </li></ul><ul><ul><li>– Oral rehydration + racecadotril 1.5 mg/kg t.i.d. </li></ul></ul><ul><ul><li>– Oral rehydration + placebo t.i.d. </li></ul></ul>Salazar-Lindo E, Santisteban-Ponce J, Chea-Wood E and Guterriez M. N Engl J Med 2000;343:463-467 INFANTS AND CHILDREN
    44. 44. <ul><li>POPULATION </li></ul><ul><ul><li>– Racecadotril + ORS: 68 patients </li></ul></ul><ul><ul><li>– Placebo + ORS: 67 patients </li></ul></ul><ul><li>EXCLUSION CRITERIA </li></ul><ul><ul><li>– Patients with diarrhea lasting for more than 5 days, blood in stools, severe dehydration (requiring IV therapy) and other illness </li></ul></ul><ul><li>INCLUSION CRITERIA </li></ul><ul><ul><li>– Boys 3 to 35 months of age </li></ul></ul><ul><ul><li>– Hospitalized because of dehydration </li></ul></ul><ul><ul><li>– With watery diarrhea for 5 days or less </li></ul></ul>Salazar-Lindo E, Santisteban-Ponce J, Chea-Wood E and Guterriez M. N Engl J Med 2000;343:463-467 RACECADOTRIL IN THE TREATMENT OF ACUTE WATERY DIARRHEA IN CHILDREN (Salazar-Lindo et al.) INFANTS AND CHILDREN
    45. 45. <ul><li>EVALUATION CRITERIA </li></ul><ul><ul><li>Primary end point : 48-hour stool output (measured in grams) </li></ul></ul><ul><ul><li>Other end points : </li></ul></ul><ul><ul><li>– Total stool output </li></ul></ul><ul><ul><li>– Duration of diarrhea </li></ul></ul><ul><ul><li>– Total ORS intake </li></ul></ul><ul><ul><li>Number of adverse events </li></ul></ul>Salazar-Lindo E, Santisteban-Ponce J, Chea-Wood E and Guterriez M. N Engl J Med 2000;343:463-467 RACECADOTRIL IN THE TREATMENT OF ACUTE WATERY DIARRHEA IN CHILDREN (Salazar-Lindo et al.) INFANTS AND CHILDREN
    46. 46. <ul><li>Characteristics of population at inclusion </li></ul>Age [months] 13 12 Weight [kg] 9.0 8.7 Duration of diarrhea before inclusion [hrs] 47.4 51.5 Stool number in the last 24 hours 8.6 9.7 Stool consistency [no. of boys] Loose 16 14 Watery 52 53 Characteristic Racecadotril + ORS Placebo + ORS [ n = 68] [n = 67] Salazar-Lindo E, Santisteban-Ponce J, Chea-Wood E and Guterriez M. N Engl J Med 2000;343:463-467 RACECADOTRIL IN THE TREATMENT OF ACUTE WATERY DIARRHEA IN CHILDREN (Salazar-Lindo et al.) INFANTS AND CHILDREN
    47. 47. <ul><li>48-hour stool output / body weight (g/kg) </li></ul>Salazar-Lindo E, Santisteban-Ponce J, Chea-Wood E and Guterriez M. N Engl J Med 2000;343:463-467 RACECADOTRIL IN THE TREATMENT OF ACUTE WATERY DIARRHEA IN CHILDREN (Salazar-Lindo et al.) INFANTS AND CHILDREN
    48. 48. <ul><li>Total stool output / body weight (g/kg) </li></ul>Salazar-Lindo E, Santisteban-Ponce J, Chea-Wood E and Guterriez M. N Engl J Med 2000;343:463-467 RACECADOTRIL IN THE TREATMENT OF ACUTE WATERY DIARRHEA IN CHILDREN (Salazar-Lindo et al.) INFANTS AND CHILDREN
    49. 49. <ul><li>Time to recovery </li></ul>Salazar-Lindo E, Santisteban-Ponce J, Chea-Wood E and Guterriez M. N Engl J Med 2000;343:463-467 RACECADOTRIL IN THE TREATMENT OF ACUTE WATERY DIARRHEA IN CHILDREN (Salazar-Lindo et al.) INFANTS AND CHILDREN
    50. 50. <ul><li>Total intake of oral rehydration solution </li></ul>Salazar-Lindo E, Santisteban-Ponce J, Chea-Wood E and Guterriez M. N Engl J Med 2000;343:463-467 RACECADOTRIL IN THE TREATMENT OF ACUTE WATERY DIARRHEA IN CHILDREN (Salazar-Lindo et al.) INFANTS AND CHILDREN
    51. 51. <ul><li>TOLERABILITY </li></ul>Adverse Events (%) Racecadotril + ORS 10 Placebo + ORS 7 The incidence of vomiting did not differ between the racecadotril and placebo groups. Salazar-Lindo E, Santisteban-Ponce J, Chea-Wood E and Guterriez M. N Engl J Med 2000;343:463-467 RACECADOTRIL IN THE TREATMENT OF ACUTE WATERY DIARRHEA IN CHILDREN (Salazar-Lindo et al.) INFANTS AND CHILDREN
    52. 52. Salazar-Lindo E, Santisteban-Ponce J, Chea-Wood E and Guterriez M. N Engl J Med 2000;343:463-467 CONCLUSION The results of this study provide evidence that racecadotril, as an adjunct to oral rehydration solution, is effective and well tolerated in reducing the duration and severity of acute watery diarrhea in hospitalized infants and children. The antidiarrheal effect is obtained more rapidly than with oral rehydration alone, particularly in infants with rotavirus infection. RACECADOTRIL IN THE TREATMENT OF ACUTE WATERY DIARRHEA IN CHILDREN (Salazar-Lindo et al.) INFANTS AND CHILDREN
    53. 53. Jean Pierre Cézard et al. Gastroenterology 2001; 120:799-805 EFFICACY AND TOLERABILITY OF RACECADOTRIL IN ACUTE DIARRHEA IN CHILDREN INFANTS AND CHILDREN
    54. 54. EFFICACY AND TOLERABILITY OF RACECADOTRIL IN ACUTE DIARRHEA IN CHILDREN ( Cézard et al.) INFANTS AND CHILDREN <ul><li>STUDY DESIGN </li></ul><ul><ul><li>– Randomized, double-blind, placebo-controlled, multicenter study </li></ul></ul><ul><li>INCLUSION CRITERIA </li></ul><ul><ul><li>– Severe acute diarrhea </li></ul></ul><ul><ul><li>– Aged 3 months to 4 years </li></ul></ul><ul><ul><li>– 3 or more watery stools per day </li></ul></ul><ul><ul><li>– Onset of diarrhea - less than 3 days </li></ul></ul><ul><li>POPULATION </li></ul><ul><ul><li>– Racecadotril + ORS: 84 patients </li></ul></ul><ul><ul><li>– Placebo + ORS: 82 patients </li></ul></ul>Cézard JP et al. Gastroenterology 2001;120:799-805.
    55. 55. <ul><li>EVALUATION CRITERIA </li></ul><ul><ul><li>– Stool output during the first 48 hrs (primary end point) </li></ul></ul><ul><ul><li>– Stool output during the first 24 hrs </li></ul></ul><ul><ul><li>– Dehydration status at 24 hrs (Urine Na + / K + ratio) </li></ul></ul><ul><ul><li>– Duration of diarrhea </li></ul></ul><ul><ul><li>– Number and characteristics of stools </li></ul></ul><ul><li>TREATMENT </li></ul><ul><ul><li>– Oral rehydration + racecadotril 1.5 mg/kg t.i.d. </li></ul></ul><ul><ul><li>– Oral rehydration + placebo t.i.d. </li></ul></ul>Cézard JP et al. Gastroenterology 2001;120:799-805. EFFICACY AND TOLERABILITY OF RACECADOTRIL IN ACUTE DIARRHEA IN CHILDREN ( Cézard et al.) INFANTS AND CHILDREN
    56. 56. <ul><li>Characteristics of population at inclusion </li></ul>CHARACTERISTIC Racecadotril + ORS Placebo + ORS [n = 84] [n = 82] Age [months] 12.0 ± 0.9 13.6 ± 1.0 Sex: [M / F] 51 / 38 50 / 33 Height [m] 0.73 ± 0.01 0.75 ± 0.01 Weight [kg] 8.54 ± 0.25 9.27 ± 0.25 Stool number [n] 6.0 ± 0.3 6.5 ± 0.4 Duration of diarrhea [days] 2.0 ± 0.2 1.9 ± 0.1 Patients with Rotavirus [n] 32 35 Patients with Adenovirus [n] 3 4 Mean + SEM Cézard JP et al. Gastroenterology 2001;120:799-805. EFFICACY AND TOLERABILITY OF RACECADOTRIL IN ACUTE DIARRHEA IN CHILDREN ( Cézard et al.) INFANTS AND CHILDREN
    57. 57. <ul><li>Stool weight (g/hour) up to 48 hours </li></ul>Cézard JP et al. Gastroenterology 2001;120:799-805. EFFICACY AND TOLERABILITY OF RACECADOTRIL IN ACUTE DIARRHEA IN CHILDREN ( Cézard et al.) INFANTS AND CHILDREN
    58. 58. <ul><li>Time to recovery in rotavirus-positive patients </li></ul>Cézard JP et al. Gastroenterology 2001;120:799-805. EFFICACY AND TOLERABILITY OF RACECADOTRIL IN ACUTE DIARRHEA IN CHILDREN ( Cézard et al.) INFANTS AND CHILDREN Duration of diarrhea [median, hours] Racecadotril [n = 32] Placebo [n = 35] P 6.9 36 0.02
    59. 59. <ul><li>TOLERABILITY </li></ul>Number of Adverse Events (AE) Racecadotril + ORS 10 Placebo + ORS 11 The incidence of adverse events was similar in both groups of patients. Most common AE: Vomiting Cézard JP et al. Gastroenterology 2001;120:799-805. EFFICACY AND TOLERABILITY OF RACECADOTRIL IN ACUTE DIARRHEA IN CHILDREN ( Cézard et al.) INFANTS AND CHILDREN
    60. 60. Cézard JP et al. Gastroenterology 2001;120:799-805. CONCLUSION This study demonstrates the efficacy (up to 50% reduction in stool output) and tolerability of racecadotril as an adjunct therapy to oral rehydration solution in the treatment of severe diarrhea in infants and children. EFFICACY AND TOLERABILITY OF RACECADOTRIL IN ACUTE DIARRHEA IN CHILDREN ( Cézard et al.) INFANTS AND CHILDREN
    61. 61. ADULTS A MULTINATIONAL COMPARISON OF RACECADOTRIL AND LOPERAMIDE IN THE TREATMENT OF ACUTE DIARRHEA IN ADULTS David Prado for the Global Adult Racecadotril Study Group Scandinavian Journal of Gastroenterology 2002
    62. 62. A MULTINATIONAL COMPARISON OF RACECADOTRIL AND LOPERAMIDE IN THE TREATMENT OF ACUTE DIARRHEA IN ADULTS (Prado D.) <ul><li>STUDY DESIGN </li></ul><ul><ul><li>– Multicenter (21 centers in 14 countries) </li></ul></ul><ul><ul><li>– Parallel groups </li></ul></ul><ul><ul><li>– Ambulatory patients </li></ul></ul>Prado D. Scand J Gastroenterol 2002;37:656-61 <ul><li>INCLUSION CRITERIA </li></ul><ul><ul><li>– 3 or more watery stools, with no visible blood, in the last 24 hours </li></ul></ul><ul><ul><li>– onset of diarrhea of presumed infectious origin, of at least 24 hours and less than 5 days </li></ul></ul>ADULTS
    63. 63. <ul><li>TREATMENT </li></ul><ul><ul><li>– Racecadotril: 100 mg, 3 times daily / Loperamide: 2 mg, 3 times daily </li></ul></ul>ADULTS <ul><li>ANALYZED POPULATION </li></ul><ul><ul><li>– Racecadotril: 461 patients / Loperamide: 454 patients </li></ul></ul>Prado D. Scand J Gastroenterol 2002;37:656-61 A MULTINATIONAL COMPARISON OF RACECADOTRIL AND LOPERAMIDE IN THE TREATMENT OF ACUTE DIARRHEA IN ADULTS (Prado D.)
    64. 64. ADULTS <ul><li>EVALUATION CRITERIA </li></ul><ul><ul><li>Main criterion : </li></ul></ul><ul><ul><li>– Duration of diarrhea until resolution, i.e 12 hours with no stools or 2 consecutive normal stools </li></ul></ul><ul><ul><li>Secondary criteria : </li></ul></ul><ul><ul><li>– Duration of abdominal distension and abdominal pain </li></ul></ul><ul><ul><li>– Associated symptoms </li></ul></ul><ul><ul><li>– Overall clinical response (success or failure) </li></ul></ul>Prado D. Scand J Gastroenterol 2002;37:656-61 A MULTINATIONAL COMPARISON OF RACECADOTRIL AND LOPERAMIDE IN THE TREATMENT OF ACUTE DIARRHEA IN ADULTS (Prado D.)
    65. 65. <ul><li>Characteristics of the patients at admission </li></ul>Included (n) 472 473 Excluded / lost from view (n) 16 / 10 17 / 10 Analyzed (n) 446 445 Age (years) * 36.4 ± 13.5 35.9 ± 12.1 Weight (kg) * 61.8 ± 12.5 62.8 ± 12.3 Male / Female 238 / 234 269 / 204 Duration of diarrhea prior to inclusion (hours) * 2.1 ± 1.1 2.1 ± 1.1 Number of watery stools in the preceding 24 hrs * 6.5 ± 4.3 6.4 ± 3.8 * means ± SEM. There was no significant difference between treatment groups PATIENTS Loperamide Racecadotril ADULTS Prado D. Scand J Gastroenterol 2002;37:656-61 A MULTINATIONAL COMPARISON OF RACECADOTRIL AND LOPERAMIDE IN THE TREATMENT OF ACUTE DIARRHEA IN ADULTS (Prado D.)
    66. 66. Duration of Diarrhea ADULTS A MULTINATIONAL COMPARISON OF RACECADOTRIL AND LOPERAMIDE IN THE TREATMENT OF ACUTE DIARRHEA IN ADULTS (Prado D.) Prado D. Scand J Gastroenterol 2002;37:656-61
    67. 67. ADULTS Prado D. Scand J Gastroenterol 2002;37:656-61 Adverse events (%) Abdominal distension (duration in hrs) A MULTINATIONAL COMPARISON OF RACECADOTRIL AND LOPERAMIDE IN THE TREATMENT OF ACUTE DIARRHEA IN ADULTS (Prado D.)
    68. 68. Treatment-related adverse events with an incidence of more than 1% Prado D. Scand J Gastroenterol 2002;37:656-61 ADULTS A MULTINATIONAL COMPARISON OF RACECADOTRIL AND LOPERAMIDE IN THE TREATMENT OF ACUTE DIARRHEA IN ADULTS (Prado D.)
    69. 69. ADULTS CONCLUSION Racecadotril resolved the symptoms of acute diarrhea rapidly and effectively, and produced more rapid resolution of abdominal symptoms and less constipation than loperamide. Prado D. Scand J Gastroenterol 2002;37:656-61 A MULTINATIONAL COMPARISON OF RACECADOTRIL AND LOPERAMIDE IN THE TREATMENT OF ACUTE DIARRHEA IN ADULTS (Prado D.)
    70. 70. RACECADOTRIL’S SAFETY AND TOLERABILITY PROFILE
    71. 71. COMPARISON OF RACECADOTRIL AND LOPERAMIDE IN CHILDREN WITH ACUTE DIARRHEA (D. Turck et al.) D. Turck et al. Aliment Pharmacol Ther 1999; 13 (Suppl. 6), 27-32. Percentage of patients with constipation SAFETY AND TOLERABILITY
    72. 72. Number of patients requiring concomitant medication during the study D. Turck et al. Aliment Pharmacol Ther 1999; 13 (Suppl. 6), 27-32. COMPARISON OF RACECADOTRIL AND LOPERAMIDE IN CHILDREN WITH ACUTE DIARRHEA (D. Turck et al.) SAFETY AND TOLERABILITY
    73. 73. PHARMACOVIGILANCE 13 th Periodic Safety Update Report for Active Substance: Racecadotril. May 2007 Laboratoires Bioprojet Pharma. Adults Infants & Children TOTAL Period covered # of reported adverse events Prevalence March 1993 to March 2007 November 2000 to March 2007 75 30 105 0.00047 % 0.00032 % 0.00042 % Prevalence of adverse events associated with Racecadotril (France) Most common AE for adults and children: “Cutaneous disorders and miscellaneous allergic reactions” SAFETY AND TOLERABILITY
    74. 74. E. Coli content of the proximal jejunum (gnotobiotic piglets) Duval-Iflah Y. Et al., Alimentary Pharmacology , 1999; (suppl. 6); 9-14 EFFECTS OF RACECADOTRIL AND LOPERAMIDE ON BACTERIAL PROLIFERATION ( Duval-Iflah Y. et al.) SAFETY AND TOLERABILITY
    75. 75. 1. Lecomte JM, Int.J. Of Antimicrobial Agents , 2000; 14:81-87 2. Scwartz J-C, Int.J. Of Antimicrobial Agents , 2000; 14:75-79 3. Duval-Iflah Y. Et al., Alimentary Pharmacology , 1999; (suppl. 6): 9-14 4. Bergmann JF et al, Alimentary Pharmacology and Therapeutics , 1992; 6:305-313 5. Knisely JS, Drug and Alcohol Dependence ,1989;23:143-151 Blood-Brain Barrier Astrocyte processes Lipid soluble transport Carrier-mediated transport Does not induce CNS Toxicity 1,2,3 Racecadotril RACECADOTRIL DOES NOT CROSS THE BLOOD-BRAIN BARRIER Does not impair mental performance 4 Has no potential for abuse or physical dependence 5 SAFETY AND TOLERABILITY
    76. 76. Therapeutic Index = LD 50 ED 50 Lecomte JM, Int.J. Of Antimicrobial Agents , 2000; 14:81-87 100 mg TID (adults) 20 times this dose was given to healthy adults with no ill effects Therapeutic dose Relevance of high therapeutic index The higher the Therapeutic Index, the lower the risk of overdose. RACECADOTRIL HAS A HIGH THERAPEUTIC INDEX (median lethal dose) (median effective dose) SAFETY AND TOLERABILITY
    77. 77. SUMMARY AND CONCLUSIONS
    78. 78. Prevention of Dehydration and Control of Diarrhea Normalization Diarrhea OVERALL CONCLUSIONS RACECADOTRIL IN THE TREATMENT OF ACUTE DIARRHEA Diarrhea Fluid replacement Racecadotril Fluid replacement
    79. 79. Normalization Diarrhea Diarrhea Racecadotril Prevention of Dehydration and Control of Diarrhea OVERALL CONCLUSIONS RACECADOTRIL IN THE TREATMENT OF ACUTE DIARRHEA Fluid replacement Fluid replacement
    80. 80. Loperamide Racecadotril Efficacy variable Motility 1 Secretion 2 Bacterial overgrowth 1 CNS effects 1 Constipation 2 - +++ - - - +++ + + + ++ RACECADOTRIL VERSUS LOPERAMIDE 1. Duval-Iflah Y. Et al., Alimentary Pharmacology , 1999; (suppl. 6); 9-14 2. D. Turck et al. Aliment Pharmacol Ther 1999; 13 (Suppl. 6), 27-32.   OVERALL CONCLUSIONS
    81. 81. Active metabolite - Thiorphan Indication - treatment of acute diarrhea Recommended dose - 100 mg capsule every 8 hours Total daily dose: - should not exceed 300 mg Duration of treatment: - should not exceed 7 days Certificate of Product Registration of Racecadotril, Bureau of Food and Drugs, Department of Health. 2005 Racecadotril summary of product characteristics RACECADOTRIL OVERALL CONCLUSIONS
    82. 82. Absorption - Rapid Maximum concentration - Maintained for at least four hours Concentration in plasma - Maintained for at least eight hours after administration RACECADOTRIL OVERALL CONCLUSIONS Racecadotril summary of product characteristics
    83. 83. Efficacy - together with ORS, significantly reduces stool output and duration of diarrhea in children and adults Safety and tolerability - similar to placebo - fewer adverse events compared with loperamide - does not induce CNS toxicity - high therapeutic index RACECADOTRIL OVERALL CONCLUSIONS
    84. 84. Racecadotril: A Novel Approach in the Treatment of Acute Diarrhea

    ×